Breast Cancer (Supportive Care) Protocol

OncologyModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Vitamin DB

2000-4000 IU daily (titrate to 40-60 ng/mL)

Promotes cell differentiation, induces apoptosis in cancer cells, and modulates immune surveillance

↓Aromatase-Inhibitor Related Joint Pain↑Breast Cancer Risk

15 studies4,800 participants

Supporting Studies (2)

PMID: 28471760 - Vitamin D and breast cancer outcomes: systematic review (2017)PMID: 24918818 - Vitamin D levels and breast cancer survival (2014)

Turkey Tail Mushroom (PSK)B

3g daily

Beta-glucans activate NK cells and macrophages, supporting immune function during treatment

↑Lymphocyte CountNatural Killer Cell Activity↑Natural Killer Cell Content

8 studies1,100 participants

Supporting Studies (2)

PMID: 22507323 - PSK immunotherapy for breast cancer: meta-analysis (2012)PMID: 28122775 - Trametes versicolor in cancer treatment (2017)

Supporting Stack

Additional supplements for enhanced results

Omega-3 Fatty AcidsB

2-4g EPA/DHA daily

May improve chemotherapy efficacy, reduce treatment-related weight loss, and decrease inflammation

10 studies800 participants

Supporting Studies (1)

PMID: 21939614 - Omega-3 fatty acids and breast cancer treatment (2011)

MelatoninB

3-20mg at bedtime

May enhance chemotherapy response, protect against treatment toxicity, and improve sleep quality

Breast Cancer Risk↑Estrogen↑IGF-1

12 studies650 participants

Supporting Studies (1)

PMID: 22271210 - Melatonin as adjuvant in breast cancer therapy (2012)

How This Protocol Works

Simple Explanation

This protocol is for supportive care during breast cancer treatment—it's designed to support the immune system, reduce treatment side effects, and potentially improve outcomes. These supplements should be used alongside, not instead of, conventional medical treatment. Always discuss with your oncologist before starting any supplements.

•Vitamin D deficiency is common in breast cancer patients and associated with worse outcomes. Vitamin D helps regulate cell growth and supports immune function. Multiple studies link higher vitamin D levels to better survival rates. Most oncologists now recommend maintaining adequate vitamin D status.

•Turkey Tail Mushroom (PSK/PSP) has been used in Japan alongside chemotherapy for decades. Its beta-glucans activate immune cells that fight cancer. Studies show it may improve survival when combined with standard treatment.

•Omega-3 fatty acids may help maintain weight and muscle mass during treatment, reduce inflammation, and possibly enhance chemotherapy effectiveness. They also support cardiovascular health during treatment.

•Melatonin can improve sleep (often disrupted during cancer treatment), may enhance chemotherapy response, and provides antioxidant protection to healthy cells.

Expected timeline: Vitamin D levels should be optimized over 2-3 months. Immune support from turkey tail develops over 4-8 weeks. Melatonin helps sleep immediately; other effects develop over weeks to months.

Important: Always inform your oncologist about supplements. Some may interact with treatments.

Clinical Perspective

Breast cancer supportive care addresses treatment-related toxicity, immune function, and modifiable risk factors for recurrence. Vitamin D deficiency and inflammation are associated with worse prognosis. This protocol focuses on evidence-based adjunctive therapies.

•Vitamin D (B-grade): VDR expressed in breast epithelium. Calcitriol induces p21 and p27 (cell cycle arrest), promotes E-cadherin (reduced metastasis), and activates apoptotic pathways. Epidemiological data show 25(OH)D >30 ng/mL associated with 44% lower mortality (PMID: 24918818). 15 studies support maintaining adequate levels. Target 40-60 ng/mL.

•Turkey Tail (PSK) (B-grade): Polysaccharide-K (PSK) from Trametes versicolor activates TLR2 on dendritic cells, enhances NK cell cytotoxicity, and increases CD8+ T-cell activity. Japanese meta-analysis of 8 RCTs (n=1100) showed improved disease-free and overall survival when added to chemotherapy (PMID: 22507323). Dose: 3g/day.

•Omega-3 Fatty Acids (B-grade): EPA/DHA reduce pro-inflammatory eicosanoids. May sensitize cancer cells to chemotherapy via membrane incorporation. Help maintain lean body mass during treatment. 10 studies show potential benefit for cachexia prevention (PMID: 21939614).

•Melatonin (B-grade): Oncostatic via MT1 receptor-mediated antiproliferative effects. Reduces angiogenesis via VEGF inhibition. May protect against chemotherapy-induced peripheral neuropathy. 12 studies show improved tumor response when combined with chemotherapy (PMID: 22271210). Dose range 3-20mg; higher doses in trials.

Biomarker targets: Serum 25(OH)D, inflammatory markers (CRP, IL-6), quality of life scores.

Protocol notes: CRITICAL: Review with oncology team. Avoid high-dose antioxidants on chemotherapy days. Vitamin D: check levels before supplementing. Turkey tail: no known drug interactions but inform oncologist. Melatonin: may affect hormone-receptor positive cancers—discuss with MD.

View All Protocols